Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE III COMPARISON OF TAXOTERE (DOCETAXEL) AND TAXOL (PACLITAXEL) IN PATIENTS WITH ADVANCED BREAST CANCER

NCT00002662 is registered in ClinicalTrials.gov with Aventis Pharmaceuticals as lead sponsor.

NCT NCT00002662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE III COMPARISON OF TAXOTERE (DOCETAXEL) AND TAXOL (PACLITAXEL) IN PATIENTS WITH ADVANCED BREAST CANCER
Lead sponsor
Aventis Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
August 31, 1994
Completion date
June 30, 2004
Enrollment
Not reported
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer